PER 0.00% 8.0¢ percheron therapeutics limited

News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review, page-7

  1. 3,225 Posts.
    lightbulb Created with Sketch. 259
    I agree BG but 16 years of non performance is very hard to digest and it shows, in fact
    regardless yesterday's two ann could be seen positive (still with too many "if & but")
    market was very cautious. Now let's see if Diamond's ability to delegate will make the most out
    of this new situation for the benefit of ANP and of course shareholders and hopefully
    will not end to the usual endless.........
    Now next should be the publication of the manuscript and JV for ATL1103
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.000(0.00%)
Mkt cap ! $72.12M
Open High Low Value Volume
7.9¢ 8.0¢ 7.9¢ $12.63K 158.7K

Buyers (Bids)

No. Vol. Price($)
2 66500 7.6¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 273231 2
View Market Depth
Last trade - 15.26pm 19/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.